Two Parks in Our City Is Chosen as a Top 100 Pharmaceutical Industry Parks in 2023

From: Lianyungang Daily Updated: 2023-07-09 03:33

Recently, CCID Consulting released 2023 Top 100 Pharmaceutical Industry Parks and 2023 Advanced Manufacturing Industry Parks. The Municipal Development Zone and Lianyungang High-tech Zone were selected as 2023 Top 100 Pharmaceutical Industry Parks, ranking 11th and 13th respectively. In addition, the Municipal Development Zone is also ranked 57th among the top 100 advanced manufacturing parks in 2023. According to the Municipal Science and Technology Bureau, “This is not only an affirmation of the pharmaceutical industry in Lianyungang, but also injects firm confidence into the pharmaceutical industry in Lianyungang, which is in a period of transformation.

Industry parks are the “main battlefield” for high-quality development of the real economy. It is known that the list is mainly oriented towards two types of parks: national high-tech zones and national economic development zones. By the end of 2022, there were 177 national high-tech zones (including Suzhou Industrial Park) and 230 national economic development zones. Compared to 2022, this year’s evaluation index system highlights the development of industrial leaps and the construction of investment environment, and adjusts the weight of indicators. At the same time, pilot innovation and transformational innovation were encouraged, and several bonus indicators were added.

The new pharmaceutical industry is the most distinctive, advantageous and promising leading industry in our city. The National New Industrialized Pharmaceutical Industry Demonstration Base in the Municipal Development Zone is the only demonstration base in the province that has been awarded a five-star rating for three consecutive years. At present, there are a total of 20 pharmaceutical enterprises above designated size in the Municipal Development Zone, including 4 enterprises with a production value of over 1 billion yuan and 2 enterprises with a production value of over 10 billion yuan. There are more than 100 affiliated supporting enterprises. Hengrui, Kanion and other four major pharmaceutical companies have been ranked among the top 40 pharmaceutical industry enterprises and the top 20 innovative enterprises in China for many consecutive years, becoming the largest production base for anti-tumor and anti-hepatitis drugs in China and an important modern Chinese medicine production base in the country. At the same time, in order to fully leverage the demonstration and driving effect of leading enterprises in accordance with a “national first-class and world-renowned” goal, the Municipal Development Zone has launched the construction of a “China Pharmaceutical Port” with a total area of 30 square kilometers, promoting the accelerated innovation cluster of the new pharmaceutical industry.

Unlike the clustering industrial development model in urban development zones, Lianyungang High-tech Zone has attracted a group of characteristic pharmaceutical enterprises to gather due to its presence on a national level high-tech zone platform. A group of small and micro technology enterprises such as Yugong Biolabs have accelerated their agglomeration in the incubator of Lianyungang High-tech Zone, gradually forming a unique competitive advantage of Lianyungang High-tech Zone. At present, the life and health industry represented by Chiatai Tianqing and LICI Medical in Haizhou Industrial Park has begun to take shape, and efforts are being made to build a high-end medical device industry clustering base.

A good industrial foundation has led to the emergence of innovative achievements in our city. After years of development, more than 20 pharmaceutical enterprises in our city have been approved for the listing of Class 1 new drugs. We have won 9 National Science and Technology Progress Awards and 5 Chinese Patent Gold Awards in total, and have undertaken over 100 national level major new drug projects in the past three years. We have also obtained nearly 50 overseas quality certification drugs. Jiangsu Hengrui Pharmaceuticals was ranked 13th in the global pharmaceutical innovation index, the only Chinese pharmaceutical enterprise on the list. Up till now, 8 national level biopharmaceutical industry bases and other scientific and technological achievements transformation bases have been approved, with over 60 pharmaceutical research and development institutions; 18 national major talent engineering experts are gathered in the field of medicine. Pharmaceutical enterprises have over 10000 high-end innovative talents.